A 'picturesque' case of transition from subcutaneous to oral treatment in neonatal diabetes.
We report a case of a 6-week-old infant with diabetes mellitus based on a genetic defect in the sulfonylurea receptor 1 (SUR1), an ATP-sensitive potassium (KATP) channel protein. A spectacular improvement in glucose regulation was shown by real-time continuous glucose monitoring when switching her from insulin to oral glibenclamide. Children with neonatal onset of diabetes deserve genetic testing in order to replace insulin with oral medication.
Department of Pediatrics, Hagaziekenhuis/Juliana Children's Hospital, The Hague, The Netherlands.
Stephanie
S
Verstappen
Department of Pediatrics, Hagaziekenhuis/Juliana Children's Hospital, The Hague, The Netherlands.
Dick
D
Mul
D000284:Administration, Oral; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D005820:Genetic Testing; D005905:Glyburide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007223:Infant; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy / Q000235:genetics; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D015221:Potassium Channels / Q000235:genetics*; D064233:Sulfonylurea Receptors / Q000235:genetics*
C577507:ABCC8 protein, human; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D015221:Potassium Channels; D064233:Sulfonylurea Receptors; D005905:Glyburide